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Patient-derived glioblastoma cells show
significant heterogeneity in treatment
responses to the inhibitor-of-apoptosis-
protein antagonist birinapant
Z Zakaria1,2, A Tivnan1, L Flanagan1, D WMurray1, M Salvucci1, B W Stringer3, B W Day3, A W Boyd3, D Ko¨gel4,
M Rehm1, D F O’Brien2, A T Byrne1 and J H M Prehn*,1
1Centre for Systems Medicine, Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin 2,
Ireland; 2National Centre for Neurosurgery, Beaumont Hospital, Dublin 9, Ireland; 3Brain Cancer Research Unit, QIMR Berghofer
Medical Research Institute, Brisbane, Queensland, Australia and 4Experimental Neurosurgery, Neuroscience Center, Frankfurt
University Hospital, Frankfurt am Main, Germany
Background: Resistance to temozolomide (TMZ) greatly limits chemotherapeutic effectiveness in glioblastoma (GBM). Here we
analysed the ability of the Inhibitor-of-apoptosis-protein (IAP) antagonist birinapant to enhance treatment responses to TMZ in
both commercially available and patient-derived GBM cells.
Methods: Responses to TMZ and birinapant were analysed in a panel of commercial and patient-derived GBM cell lines using
colorimetric viability assays, flow cytometry, morphological analysis and protein expression profiling of pro- and antiapoptotic
proteins. Responses in vivo were analysed in an orthotopic xenograft GBM model.
Results: Single-agent treatment experiments categorised GBM cells into TMZ-sensitive cells, birinapant-sensitive cells, and cells that
were insensitive to either treatment. Combination treatment allowed sensitisation to therapy in only a subset of resistant GBM cells.
Cell death analysis identified three principal response patterns: Type A cells that readily activated caspase-8 and cell death in
response to TMZ while addition of birinapant further sensitised the cells to TMZ-induced cell death; Type B cells that readily activated
caspase-8 and cell death in response to birinapant but did not show further sensitisation with TMZ; and Type C cells that showed no
significant cell death or moderately enhanced cell death in the combined treatment paradigm. Furthermore, in vivo, a Type C patient-
derived cell line that was TMZ-insensitive in vitro and showed a strong sensitivity to TMZ and TMZ plus birinapant treatments.
Conclusions: Our results demonstrate remarkable differences in responses of patient-derived GBM cells to birinapant single and
combination treatments, and suggest that therapeutic responses in vivomay be greatly affected by the tumour microenvironment.
Glioblastoma multiforme or glioblastoma (GBM) is a grade IV
astrocytoma and accounts for 50–60% of all intracranial gliomas,
carrying the worst prognosis of all cancers (Louis et al, 2007;
Filippini et al, 2008). As per Stupp protocol, standard therapy
consists of concomitant temozolomide (TMZ) and radiotherapy
followed by adjuvant TMZ (Stupp et al, 2005). TMZ treatment
leads to formation of the cytotoxic DNA lesion O6-methylguanine
(O6-MeG) and, ultimately, apoptosis of tumour cells (Roos et al,
2007). The evasion of apoptosis is a typical hallmark of cancer
(Hanahan and Weinberg, 2000). Inhibitor-of-apoptosis-proteins
(IAPs) were originally discovered in baculoviruses two decades ago
due to their ability to suppress the host cell death response during
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viral infection (Birnbaum et al, 1994). Cellular-IAP-1 (cIAP1),
cIAP2 and X-linked-IAP (XIAP) block apoptosis by interfering
with the activation of caspases in both the extrinsic and intrinsic
apoptosis pathways (Fulda, 2014). The extrinsic pathway is
initiated by ligands that are recognised by cell surface
death receptors, such as Fas, tumour necrosis factor (TNF) or
TNF-related apoptosis inducing ligand receptors (Chou et al,
2015). Upon activation, this promotes the assembly of three core
proteins; receptor-interacting protein 1 (RIP1)/Fas-associated
protein with death domain (FADD)/caspase-8 that can directly
cleave procaspase-3 and -7 or activate necroptosis and other
signalling pathways (Fulda, 2014). cIAP1 and cIAP2 regulate death
receptor signalling mainly by means of their E3 ubiquitin ligase
activity (Varfolomeev et al, 2007; Park et al, 2009). Meanwhile, the
intrinsic pathway involves the activation of caspases-3 and -7 via
mitochondrial permeabilisation and the subsequent release of
cytochrome c and Smac into the cytosol. Cytochrome c triggers the
formation of the apoptosome, a multiprotein complex comprising
of apoptotic-protease-activating-factor 1, procaspase-9, dATP/ATP
and cytochrome c (Li et al, 1997; Zou et al, 1997). The apoptosome
complex subsequently activates effector caspases-3 and -7. XIAP
acts in this pathway to inhibit caspase-3, -7 and -9 activity (Lacasse
et al, 2008). Smac released during apoptosis binds XIAP and
inhibits its activity (Fulda, 2014).
Many human tumours such as high-grade glioma express high
levels of IAPs and aberrant expression has been linked to a defect
in apoptosis, therapy resistance and poor prognosis (Lacasse et al,
2008; Vellanki et al, 2009; Murphy et al, 2013). It has been
rationalised that removal of these barriers helps the diseased cells
to enter apoptosis (Straub, 2011). Birinapant is a small molecule
IAP antagonist currently in phase II clinical trials (www.clinical-
trials.gov) with proven efficacy in inducing apoptosis in non-CNS
malignancies where the IAPs are frequently overexpressed, such as
melanoma, leukaemia, breast and colorectal cancer Allensworth
et al, 2013; Krepler et al, 2013; Benetatos et al, 2014). The dimeric
structure of this molecule provides advantages in terms of higher
binding affinities and potency to promote caspase activation,
ubiquitination and proteasomal degradation of IAPs (Varfolomeev
et al, 2007; Vince et al, 2007; Krepler et al, 2013; Fulda, 2014).
Little, however, is known about the efficacy of birinapant in
CNS malignancy. Previous studies have demonstrated significant
potential of Smac mimetics in combination with death receptor
agonists in GBM cell lines (Wagner et al, 2013; Fulda, 2014).
To explore the potential of birinapant as a therapeutic in GBM, we
performed a comprehensive study to explore the sensitivity of a
large panel of GBM cell lines to birinapant single and combination
treatment with TMZ. Because response of GBM cells to birinapant
treatment in vitro could differ when these cells are implanted
in vivo (Eytan et al, 2015), we also investigated treatment responses
in an orthotopic intracranial GBM model.
MATERIALS AND METHODS
Cell cultures. Commercially available GBM cell lines were obtained
from American Type Culture Collection. Established MZ-derived
GBM cell lines were obtained from Professor Donat Ko¨gel (University
Hospital, Frankfurt, Germany) (Hetschko et al, 2008). The cells were
grown in complete growth medium as previously described (Murphy
et al, 2013). Isolation of patient tumours for the generation of low-
passage primary patients GBMs was approved by the human ethics
committee of the Queensland Institute of Medical Research and Royal
Brisbane and Women’s Hospital (Day et al, 2013). The cells were
grown in serum-free culture medium on 1% matrigel-coated flasks, as
previously described (Pollard et al, 2009). All cells were maintained in
an incubator at 37 1C in humidified air with 5% CO2.
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay. Glioblastoma cell lines were plated in 96-well plates
(2 103 cells per well), treated with TMZ (150 mM) and/or
birinapant (1mM) and a cell viability assay was carried out for
the indicated time points as previously described (Murphy et al,
2013). Cell viability was determined by calculating relative
changes of absorbance compared with the controls, which was
set to 100% viability.
Western blotting. Glioblastoma cell lines were plated in six-well
plates (8 104 cells per well), treated with TMZ (150mM) and/or
birinapant (1mM) for 96h. Western blotting was performed as
described previously (Murphy et al, 2013) using the following
antibodies at 1 : 1000 dilution: XIAP (Cell signalling Technology,
Beverly, MA, USA), FADD (BD Biosciences, Oxford, UK), caspase-8
(ENZO Life sciences (UK) Ltd., Exeter, UK), cIAP1 (R&D Systems,
Abingdon, UK), and cIAP2 and RIP1 (Abcam, Cambridge, UK).
Actin (Abcam) at 1 : 5000 dilution was used for loading control.
Chemiluminescence signal was detected using LAS-3000 Imager
equipped with a cooled 12 bit digital CCD camera (FUJIFILM UK Ltd
Systems, Sheffield, UK). All western blots shown are representative of
two to three independent experiments with similar results.
Flow cytometry. Glioblastoma cell lines were plated in 24-well
plates (1 104 cells per well), pretreated with of zVAD (50 mM) for
60min and then treated with TMZ (150 mM) and/or birinapant
(1 mM) for 96 h. Following treatment, monolayer cells were
harvested with trypsin-EDTA or accutase, and were then incubated
in binding buffer (10mM HEPES, 135mM NaCl, 5mM CaCl2),
containing 1 ml ml 1 of annexin V-FITC conjugate and/or
1 mgml 1 of propidium iodide (PI) (Bio Vision, Mountain View,
CA, USA) for 15min on ice. Cells were counted in a Partec Cyflow
ML16 flow cytometer (Partec, Mu¨nster, Germany). Annexin
V-FITC was excited with the 488 nm laser, and fluorescence
emission was collected in the FL1 channel through a 520 nm band
pass filter. PI was excited with the 488 nm laser, and fluorescence
emission was collected in the FL2 or FL3 channel through
575–605 nm or 630 nm band pass filter, respectively. Compensa-
tion for crosstalk was performed as required. In total, 1 104 gated
cells were required for each sample.
Hoechst staining and phase contrast microscopy. GBM cell lines
were plated in 24-well plates (1 104 cells per well) and treated
with TMZ (150 mM) and/or birinapant (1mM) for 96 h. Hoechst and
phase contrast images was performed as described previously
(Murphy et al, 2013). Using Image J software (NIH, USA), those
cells with condensed/fragmented nuclei were deemed apoptotic,
counted and expressed as a percentage of the apoptotic cells per
treatment group.
In vivo orthotopic xenograft GBM studies. All animal experi-
ments were licensed by the Department of Health and Children,
Dublin, Ireland. Protocols were reviewed by the Royal College of
Surgeons in Ireland Research Ethics Committee. Forty female
NOD/SCID mice (5–6 week) were purchased from Charles River
Laboratories (Canterbury, UK) and maintained in isolated facility
within a specific pathogen-free environment. RN1luc cells
(5 105) stably expressing luciferase were selected for xenograft
studies. The experimental techniques for orthotopic implantation
and bioluminescence imaging (BLI) were performed as previously
described (Jarzabek et al, 2013). Once the tumour reached
exponential growth phase, animals were randomised into four
groups: vehicle, TMZ, birinapant and TMZ plus birinapant (n¼ 10
mice per cohort). TMZ (25mg kg 1 formulated in 10% DMSO in
sterile PBS 7 days) was delivered via oral gavage. Animals
received birinapant via an intraperitoneal injection (i.p.)
(20mg kg 1 every 3 days (nine doses in total)). The combination
group received both drugs. Animals were killed when moribund.
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Statistics. Detail of statistical analysis is available in Supplementary
data.
RESULTS
GBM cells show a heterogeneous sensitivity to TMZ and
birinapant single treatment with enhanced sensitisation
achieved with combined treatment. Reflecting the heterogeneity
of GBM cells, we used a panel of 15 GBM cell lines, which
consisted of five commercially available GBM cell lines (U87,
U251, A172, U343 and U373), a cohort of cell lines derived from
patient GBMs including four primary (MZ294, MZ327, MZ51 and
MZ18) and two recurrent tumours (MZ304 and MZ256)
(Hetschko et al, 2008), and four cell lines from low-passage
primary patient GBMs (JK2luc, WK1luc, RN1luc and SJH1luc)
(Day et al, 2013; Tivnan et al, 2014). The cells were incubated with
TMZ at 150 mM (Murphy et al, 2013), and/or birinapant at 1mM,
a concentration that has been proven to be pharmacodynamically
active in cancer cell lines (Allensworth et al, 2013; Krepler et al,
2013). Cell viability was analysed at five different time points using
the MTT assay.
Following analysis of cell line responses, three distinct response
patterns were observed; TMZ-sensitive cells, birinapant-sensitive
cells, as well as cells that were insensitive to either treatment
(Figure 1). During the first 48 h of incubation, TMZ and birinapant
single treatments were not effective in inducing cell death, with cell
viability remaining aboveB80%. Sensitive cells responded to TMZ
treatment earlier than birinapant, with two of the commercially
available cell lines (A172 and U251) showing TMZ sensitivity at
72 h post treatment onset (Po0.05). All commercially available
GBM cell lines showed persistent reduction in cell survival at 96 h
of treatment (Figure 1A). The cells that were insensitive to either
treatment showed no significant effect on cell survival despite the
prolonged incubation periods (Figure 1B, C, E and F). In contrast,
birinapant-sensitive cell lines comprised of a mixture of the
commercial and patient-derived GBMs, with a moderate reduction
in cell viability evident at 96 h in 4 (A172, U251, U87 and JK2luc),
and at 120 h in 7 of the 15 cell lines investigated (Figure 1D).
Following combination treatments of TMZ plus birinapant, the
cells were further categorised into four distinct response patterns.
During the first 48 h of incubation, two cell lines (A172 and U251)
that were sensitive to both TMZ and birinapant single treatments
were below 80% survival in the combined regimen (Figure 1G;
Po0.05), with further reductions observed at 72 h of treatment.
A similar effect was observed in TMZ-sensitive U373 cells where a
significant reduction of cell survival was evident at 72 h of
treatment, and in two birinapant-sensitive cell lines (RN1luc and
JK2luc) at 96 h (Figure 1H; Po0.05). Two cell lines (WK1luc and
MZ18) that were resistant to both single treatments were sensitised
after 96 h of treatment, with a further (MZ327) at 120 h (Figure 1I;
Po0.05). Nevertheless, four GBM cells (MZ294, SJH1luc, MZ51
and MZ256) remained resistant even to a combined treatment over
120 h (Figure 1J). Together, this set of experiments demonstrated
that birinapant treatment differentially sensitised GBM cells to
TMZ, with a subset of cell lines permitting an additional
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Figure 1. Effect of single and combination treatments on cell survival in a panel of GBM cells. (A–C) The characteristics of TMZ-sensitive
cells were observed at 72 h post treatment, (D–F) whereas birinapant-sensitive cells at 96 h post treatment. (G) For combination treatments,
additional reduction in cell survival were evident at 48 h post treatment in cells that were sensitive to TMZ and birinapant single treatment, (H) and
at 72 h post treatment in TMZ- or birinapant-sensitive cells. (I) Three of the GBM cells that were resistant to single treatments had benefited
from combined treatments. (J) Four of the GBM cells remained resistant to the treatments. One-way ANOVA, *Po0.05, **Po0.01, ***Po0.001.
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sensitisation of cells that were resistant to single treatments. For
subsequent experiments, two GBM cells from each groups were
selected; U87 and U251 (commercially available GBM cells),
MZ294 and MZ304 (primary and recurrent MZ-derived patient
GBMs) and RN1luc and WK1luc (low-passage luciferase positive
primary patient GBMs).
Evaluation of IAP proteins levels in GBM cells treated with TMZ
and birinapant. To validate that birinapant targeted IAPs in the
selected cell lines, western blot analysis of cIAP1, cIAP2 and
XIAP protein levels was conducted (Figure 2). Following 96 h of
treatment, birinapant as a single agent as expected caused the
degradation of cIAP1, as the protein is auto-ubiquitinated and
degraded via the proteasome in response to IAP antagonist
treatment (Fulda, 2014). We observed degradation of cIAP1 in all
selected GBM cells, with U251 cells showing complete degrada-
tion only in response to the TMZ plus birinapant or TMZ single
treatment. There was little evidence for significant changes in
cIAP2 and XIAP protein levels in line with the fact that
autoubiquitination, and proteasomal degradation is a feature of
cIAP1 but not cIAP2 and XIAP (Vince et al, 2007; Condon et al,
2014). Exceptions to this were U251 cells where the exposure to
TMZ alone and in combination with birinapant induced
degradation of cIAP2 and XIAP, and MZ304 where the exposure
to birinapant alone or in combination with TMZ induced
degradation of XIAP.
Cell death analysis after TMZ and birinapant single and
combined treatments identifies three principal cell death
response patterns. In order to further elucidate this apparent
heterogeneity in treatment responses, we performed a more
detailed analysis of cell death pathways activated or not in
response to TMZ and birinapant. Flow cytometry analysis of PI
uptake and annexin V-FITC staining was conducted following 96 h
of treatment with single or combination therapies, both in the
presence and absence of the caspase inhibitor, zVAD. Cells positive
for annexin V binding (as a marker for apoptosis activation) and
PI-positive cells (cells that underwent membrane rupture after
‘primary’ of ‘secondary necrosis’) were quantified (Henry et al,
2013). To further characterise the morphology of GBM cells, the
condensation and fragmentation of nuclei was assessed using
Hoechst staining.
In agreement with the MTT assay data, cell death analysis in
response to single and combined treatments identified three major
principal response patterns. The first response pattern (‘Type A’
cell) was seen in TMZ-sensitive U251 cells. Flow cytometry
analysis showed significant apoptotic and ‘secondary necrotic’ cell
death in response to TMZ but not birinapant, which was sensitive
to zVAD treatment (Figure 3A–D). Similar response patterns were
identified in U87 cells (Supplementary Figure 1). Combined
treatment with birinapant further enhanced cell death, a finding
also confirmed by morphological analysis of nuclear condensation
(Figure 3E and F). Western blot analysis after 96 h of treatment
demonstrated processing of procaspase-8 into p41 and p18
subunits, indicative of caspase-8 activation. This was accompanied
by an increase in FADD protein levels and a decrease in RIP1
protein levels (Figure 3G).
A second principal response pattern (‘Type B’ cell) was seen in
the birinapant-sensitive WK1luc cells. Flow cytometry analysis
revealed increases in PI uptake in response to birinapant or
birinapant plus TMZ, but not to TMZ alone (Figure 4A–D). Cell
death was completely inhibited by the caspase inhibitor zVAD.
Cell death activation was confirmed by a quantitative analysis of
cell death using Hoechst staining (Figure 4E and F). Western blot
analysis indicated that birinapant treatment readily activated
caspase-8, and led to an increase in FADD and reduction in
RIP1 protein levels (Figure 4G).
A third response pattern (‘Type C’ cell) was seen in RN1luc,
MZ294 and MZ304 cells that showed moderate (RN1luc and
MZ304) or no response (MZ294) to birinapant or birinapant plus
TMZ treatments in the previous MTT assays. Flow cytometry
analysis revealed that RN1luc cells showed moderate sensitisation
to cell death with the combined treatment. This reached the level of
statistical significance in the flow cytometry and Hoechst staining
experiments. This sensitisation was sensitive to zVAD treatment
(Figure 5A–F). Western blot analysis of RN1luc cells demonstrated
no detectable caspase-8 activation and a loss of RIP1 protein
levels following birinapant treatment (Figure 5G). MZ294 and
MZ304 showed no effects of the combined treatments on cell
death as measured by PI uptake (Supplementary Figure S2).
MZ294 and MZ304 cells showed moderate annexin V-FITC
staining and nuclear condensation in response to TMZ plus
birinapant by flow cytometry analysis and Hoechst staining that
was sensitive to zVAD.
In vivo analysis of ‘Type C’ RN1luc cells in an intracranial
xenograft model. Type C RN1luc cells that stably expressing
luciferase was next selected to determine whether sensitisation
could be achieved in vivo, following orthotopic intracranial tumour
cell delivery. Treatment commenced 63 days following tumour cell
inoculation. Figure 6A presents study time points for drug
combination treatment with weekly BLI performed. Birinapant
treatment had no impact on tumour growth as reflected by an
increasing bioluminescent signal similar to the vehicle group
(P¼ 0.2420). In contrast, TMZ and TMZþ birinapant significantly
inhibited tumour growth (Po0.0001 for both). TMZþ birinapant
treatment did not have a significantly greater tumour growth
inhibitory effect when compared with TMZ after adjustment for
multiple testing (P¼ 0.9116), however, a significant effect was
observed when TMZ and TMZþ birinapant were compared with
birinapant (Po0.0001 for both). Nevertheless, after 49 days post
treatment, tumour growth inhibition was greatest in the TMZþ
birinapant group (Figure 6B). Bioluminescent images of represen-
tative mice from experimental cohort at 35 or 84 days post
treatment commencement are shown in Figure 6C.
Survival analysis revealed that TMZ and TMZþ birinapant
elicited a significant survival benefit, with median survival
of 161.5 days and 173.5 days, respectively, compared with
vehicle (92.5 days; Po0.0001 for both) (Figure 6D). Comparing
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median survival between animals in birinapant and vehicle
cohorts, we found no significant difference (P¼ 0.042)
after adjustment for multiple testing, suggesting that the
survival benefit was due to tumour sensitisation with TMZ.
Although the addition of birinapant to TMZ treatment elicited
a modest median survival advantage of 12 days (P¼ 0.0293)
compared with TMZ animals, this was not statistically
significant.
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DISCUSSION
The development of IAP antagonists as potential anticancer
agents has gained significant interest as inhibition of IAPs has
been shown to sensitise various cancer cells to pro-apoptotic
agents (Varfolomeev et al, 2007; Fulda, 2014). Our result show
surprisingly heterogeneous responses in commercial and patient-
derived GBM cells treated with birinapant in vitro, either as a
single agent or when combined with TMZ. Heterogeneous
responses to Smac mimetics have been reported in non-small-
cell lung cancer cells and A172 cells (Petersen et al, 2010; Wagner
et al, 2013), whereas other reports described more homogeneous
effects in acute myeloid leukaemia, and breast cancer cells
(Benetatos et al, 2014; Carter et al, 2014). Responses to TMZ,
birinapant and the combination of TMZ plus birinapant could be
classified into three principal response patterns: Type A cells
showing cell death in response to TMZ, with addition of
birinapant showing further sensitisation to TMZ induced cell
death; Type B cells showing responses to birinapant but no
further sensitisation with TMZ; and Type C cells showing no
significant cell death or moderately enhanced cell death in the
combined treatment paradigm. Furthermore, we show that
responses to patient-derived GBM cells in vivo may increase
significantly when compared with responses in vitro, suggesting
that the tumour microenvironment has an important role in
treatment responses.
We noted that all commercially available GBM cell lines
were TMZ-sensitive and all patient-derived GBM cell lines were
TMZ-resistant. In contrast, ‘responders’ to birinapant were
observed in both groups, albeit the magnitude of responses to
single-agent birinapant treatment was significantly smaller in both
commercial and patient-derived GBM cells. This finding highlights
the importance of the inclusion of patient-derived GBM cells in
preclinical in vitro and in vivo studies. In addition, MGMT status
alone has not been found to correlate to the TMZ responsiveness
in vivo in the patient-derived cell lines assessed in this study
(Murphy et al, 2013).
The Type A cells (such as U251 cells) were sensitive to TMZ and
showed further sensitisation when the treatment was combined
with birinapant. The mode of cell death was mainly apoptotic or
‘secondary’ necrotic, as identified by annexin V and PI uptake and
protection with the caspase inhibitor zVAD. Activation of
apoptosis is consistent with the DNA damage response induced
by TMZ (Roos and Kaina, 2013), which triggers caspase activation
(Roos et al, 2007). Sensitisation of GBM cells towards TMZ-
induced apoptosis by birinapant or other Smac mimetic has
previously been demonstrated to involve caspase-8 activation as a
key mechanism (Wagner et al, 2013). We also noted that RIP1
protein levels were low in response to TMZ and TMZ plus
birinapant, likely a consequence of caspase-8 activation (Lin et al,
1999). Interestingly, absence or low expression of cleaved caspase-8
and overexpression of RIP1 have been shown to serve as
independent negative prognostic indicators in GBM (Park et al,
2009; Saggioro et al, 2014).
The Type B cells (such as WK1luc cells) were sensitive to single-
agent birinapant treatment, but no further sensitisation with TMZ
was observed. Birinapant or birinapant plus TMZ treatment
induced ‘secondary’ necrotic cell death that was zVAD-sensitive
(annexin V and PI-positive cells). We also observed annexin
V-positive and PI-negative cells. This cell death was, however, also
zVAD-sensitive, and Hoechst staining indicated strong nuclear
condensation, indicating that these cells did not undergo a primary
necrotic cell death. The appearance of such double-positive cells is
likely a consequence of ruptured membranes late during apoptosis
that sheared off apoptotic nuclei during flow cytometric sample
reading. Cell death in response to birinapant was associated with a
strong FADD and procaspase-8 upregulation, suggesting that
birinapant treatment enabled the formation of caspase-8 activating
platforms such as the ripoptosome (Varfolomeev et al, 2007; Bai
et al, 2014). Western blot experiments also demonstrated caspase-8
activation and reduced RIP1 protein levels. Cleavage of RIP1 by
caspase-8 has previously been reported (Lin et al, 1999).
The Type C cells (such as RN1luc, MZ294 and MZ304 cells)
however were largely resistant to either single treatment and only
capable of activating moderate cell death when the treatments were
combined. In MZ294 cells, we noted significant annexin V binding,
which was blocked by zVAD, yet only a small fraction of cells
eventually underwent cell death. A ‘sublethal’ apoptosis activation
was confirmed in our western blot analysis, where the treatments
failed to activate caspase-8 and where FADD expression remained
stable. Activation of caspase-8, therefore, may represent a better
predictor of birinapant and TMZ responsiveness in GBM cells than
annexin V binding. Western blot analysis showed downregulation
of cIAP1 protein in all GBM cell lines tested. It can therefore be
concluded that the downregulation of cIAP1 protein levels were
not sufficient to activate caspase-8 and promote cell death in type
C cells. This has previously not been noted in other cellular models
(Tenev et al, 2011; Wagner et al, 2013).
Although many ongoing (pre)clinical trials for birinapant,
either alone or in combinations with other chemotherapy
agents were conducted on non-CNS cancer, we elucidated the
role of birinapant as a targeted therapy for GBM in an orthotopic
model. From the observed Type C RN1luc cells response
pattern in vitro, the therapeutic potential of birinapant in vivo
were predicted to be limited, even with the combined treatment.
The RN1luc cells, to our surprise, exhibited sensitivity and
antitumour activity to TMZ and TMZ plus birinapant treatment
in vivo. RN1luc cells are MGMT unmethylated (Tivnan et al,
2014), and yet in vivo treatment showed a surprising
sensitivity to TMZ. It has been shown that GBM cells with
unmethylated MGMT promoter remain resistant to TMZ
treatment after a single and repeated in vitro exposure, but
become highly sensitive when treated in vivo (Kitange et al,
2009). In addition, culturing cells via monolayer (2D, adherent)
could limit the efficacy of chemotherapeutics agents. Even with
the improved monolayer technique as applied in this study
(described by Pollard et al, 2009), the methylation and
transcription profiles between in vitro and in vivo models
have been shown to be different (Baysan et al, 2014). Important
signals and key regulators needed for drug uptake into the
cells or drug action could occur naturally within in vivo
microenvironment. Although literature is still lacking in studies
of relevance of TMZ treatment on tumour stroma cells
(Jones and Holland, 2012), it is possible that the stroma cells
are also important for drug actions in vivo.
The effects of birinapant single-agent treatments in vivo were
less pronounced, as predicted from our in vitro studies. We cannot
fully exclude that birinapant has limited blood–brain barrier
permeability, preventing the molecule to reach its target. However,
a role for TMZ in increasing the permeability of the blood–brain
barrier to allow co-treated drugs to reach the tumour cells has been
reported (Riganti et al, 2014). This could explain the tendency
towards an increased survival advantage in the TMZ plus
birinapant group.
In conclusion, our data demonstrate that GBM cells show
heterogeneous treatment responses in vitro to birinapant alone
or in combination with TMZ, and can be principally subgrouped
into three different response patterns. Furthermore, we demon-
strate that tumour microenvironment affects GBM cells sensi-
tivity to TMZ and combined TMZ and birinapant treatment. Our
findings also give an insight into the challenges of identifying
new treatments for GBM, and highlight the importance of
intracranial GBM models in such studies.
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